BT-474-luc Orthotopic Mouse Model Service for Breast Cancer

The BT-474-luc orthotopic mouse model integrates a stably expressed firefly luciferase reporter into the HER2+⁺/ER+⁺/PR+⁺ luminal B breast cancer background, enabling noninvasive, real-time bioluminescence tracking of tumor burden and metastatic dissemination within the orthotopic mammary microenvironment. Alfa Cytology delivers comprehensive BT-474-luc orthotopic programs that pair precision surgical implantation with longitudinal bioluminescence imaging, quantitative tumor growth analysis, and terminal molecular characterization to provide dynamic, high-resolution preclinical datasets for your targeted therapy and metastasis research.

Overview of BT-474-luc Orthotopic Mouse Model for Breast Cancer

BT-474-luc is a luciferase-engineered derivative of the human BT-474 breast ductal carcinoma cell line, retaining the parental line's luminal B molecular signature—robust co-expression of estrogen receptor (ER^α), progesterone receptor (PR), and HER2/neu (ErbB2)—while gaining the ability to emit bioluminescent signals upon systemic administration of D-luciferin substrate. When introduced orthotopically into the mammary fat pad of immunodeficient hosts such as nude (Nu/Nu) or NOD scid gamma (NSG) mice, BT-474-luc tumors establish within their native tissue context and permit serial, noninvasive visualization of primary lesion expansion as well as early detection of spontaneous metastasis to draining lymph nodes, lung, liver, and bone.

Fig 1. BT-474 cells were stereotactically injected into the brains of nude mice to establish xenografts, and the efficacy of intra-arterial trastuzumab treatment was evaluated by multiparametric MRI. (Kim, Bo Kyu, et al., 2024)

The incorporation of firefly luciferase transforms this model into a powerful longitudinal imaging platform. Because bioluminescence intensity scales with viable tumor cell mass and requires both ATP and oxygen, signal output directly reflects metabolically active tumor burden rather than necrotic or fibrotic tissue. This property makes BT-474-luc uniquely suited for assessing therapeutic response kinetics, detecting micrometastatic seeding before palpable lesions form, and reducing cohort sizes by allowing each animal to serve as its own control across multiple time points—advantages that are unattainable with conventional caliper-based measurements alone.

Cell Line Information: BT-474-luc

BT-474-luc was generated by stable transduction of the parental BT-474 cell line with a firefly luciferase expression cassette, enabling quantitative light emission that correlates linearly with viable cell number over several orders of magnitude. The reporter construct is typically driven by a constitutive promoter such as CMV or EF1_α and is maintained under antibiotic selection to ensure stable inheritance during in vitro expansion and in vivo propagation. The resulting line preserves the parental BT-474 epithelial-like morphology, hormone receptor profile, and HER2 amplification status while adding real-time imaging capability.

Our Services

Alfa Cytology specializes in BT-474-luc orthotopic model construction paired with longitudinal bioluminescence imaging, offering end-to-end preclinical services that encompass luciferase-expressing cell authentication, surgical implantation, weekly BLI acquisition, quantitative photon flux analysis, and comprehensive terminal histopathology to accelerate your HER2-targeted or endocrine-combination therapeutic development with dynamic, reproducible imaging data.

Workflow of BT-474-luc Orthotopic Mouse Model Construction

Establishing a BT-474-luc orthotopic model requires coordinated execution of cell culture, surgical implantation, and imaging calibration to ensure robust bioluminescent signal detection throughout the study duration. The protocol outlined below integrates quality-controlled cell preparation with standardized surgical and imaging procedures.

1. Reporter Line Authentication and Expansion: Low-passage BT-474-luc cells are expanded under antibiotic selection, authenticated by STR profiling, and validated for luciferase expression via in vitro bioluminescence assay with D-luciferin; ER^α/PR/HER2 expression is confirmed by flow cytometry.
2. Host Selection and Acclimatization: Female immunodeficient mice (Nu/Nu or NSG, 6–10 weeks) are quarantined, health-screened, and randomized by body weight to minimize inter-animal variability.
3. Single-Cell Suspension Preparation: Adherent clusters are gently dissociated with trypsin-EDTA, triturated to disrupt aggregates, passed through a 40 µm strainer, and resuspended at 1 × 10⁷ cells/mL in ice-cold PBS/Matrigel; viability exceeds 98% by trypan blue exclusion.
4. Anesthesia and Surgical Site Preparation: Mice receive isoflurane inhalation anesthesia; the fourth mammary gland region is shaved, sterilized with alternating povidone-iodine and ethanol, and draped aseptically.
5. Orthotopic Cell Inoculation: A 100 µL suspension containing 1 × 10⁶ BT-474-luc cells is injected directly into the exposed mammary fat pad through a 27-gauge needle under direct visualization, ensuring deposition within the adipose stroma rather than the peritoneal cavity.
6. Wound Closure and Postoperative Care: The skin incision is closed with sterile wound clips or sutures; postoperative analgesia is administered, and animals recover on a heated pad under continuous observation until fully ambulatory.
7. Baseline Bioluminescence Imaging: Within 24–72 hours post-implantation, mice receive an intraperitoneal injection of D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS system to confirm successful engraftment and establish baseline photon flux.
8. Longitudinal Tumor Monitoring: Tumors are tracked twice weekly by digital calipers (V = 0.5 × L × W²) and once weekly by BLI; upon reaching 150–250 mm³, mice are randomized into treatment and vehicle-control cohorts based on matched bioluminescent signal and tumor volume.
9. Endpoint Imaging and Tissue Harvest: At study termination, a final BLI scan is performed, followed by euthanasia; primary tumors are excised, weighed, and imaged ex vivo, while draining lymph nodes, lungs, liver, and bone are collected for metastasis quantification by ex vivo BLI and histopathology.

Fig 2. BT-474-luc Orthotopic Mouse Model construction workflow.

Case Study-BT-474-luc Orthotopic Mouse Model Development

In a preclinical imaging study, the BT-474-luc orthotopic model was employed to evaluate the antitumor efficacy of a novel HER2-directed antibody-drug conjugate administered as monotherapy or in combination with an endocrine agent. Longitudinal bioluminescence imaging captured real-time changes in primary tumor photon flux, enabling early detection of treatment-induced regression, while ex vivo BLI of resected organs quantified metastatic burden in lymph nodes and pulmonary tissue, yielding pharmacodynamic insights into both local and systemic therapeutic activity.

Why Choose Alfa Cytology?

Alfa Cytology pairs deep expertise in orthotopic xenograft surgery with advanced bioluminescence imaging infrastructure to deliver BT-474-luc programs that generate dynamic, quantitative, and publication-ready datasets for your preclinical pipeline.

• Luciferase-Integrated Imaging Platform: Dedicated IVIS capability for longitudinal BLI acquisition, photon flux quantification, and spectral unmixing to track tumor burden and metastasis in real time.
• Orthotopic Surgical Precision: Standardized mammary fat pad implantation protocols optimized for luciferase-labeled cell lines, ensuring high engraftment rates and consistent bioluminescent signal kinetics.
• Dual-Endpoint Capability: Simultaneous caliper-based volumetrics and BLI signal tracking provide complementary growth data, with ex vivo BLI validation of metastatic sites at necropsy.
• HER2/HR Combination Study Design: Proven experience designing BLI-guided efficacy studies for anti-HER2 biologics, endocrine therapies, and their synergistic combinations in the luminal B context.
• Reduced Animal Usage: Longitudinal BLI allows each animal to serve as its own control across multiple time points, improving statistical power while aligning with 3R principles.

Contact Us

If your research demands real-time visualization of tumor dynamics and metastatic progression in a HER2+⁺/hormone receptor-positive breast cancer setting, Alfa Cytology is equipped to deliver. Reach out to us today to discuss your BT-474-luc orthotopic imaging study, and our team will craft a longitudinal BLI program tailored to your therapeutic hypotheses and discovery milestones.

For research use only. Not intended for any clinical use.